270 related articles for article (PubMed ID: 8111066)
21. von Willebrand factor competes with fibrin for occupancy of GPIIb:IIIa on thrombin-stimulated platelets.
Hantgan RR; Nichols WL; Ruggeri ZM
Blood; 1990 Feb; 75(4):889-94. PubMed ID: 2302458
[TBL] [Abstract][Full Text] [Related]
22. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
23. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
24. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop.
Stringer HA; van Swieten P; Heijnen HF; Sixma JJ; Pannekoek H
Arterioscler Thromb; 1994 Sep; 14(9):1452-8. PubMed ID: 8068607
[TBL] [Abstract][Full Text] [Related]
25. Factor XIIIa binding to activated platelets is mediated through activation of glycoprotein IIb-IIIa.
Cox AD; Devine DV
Blood; 1994 Feb; 83(4):1006-16. PubMed ID: 7906563
[TBL] [Abstract][Full Text] [Related]
26. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis.
Loza JP; Gurewich V; Johnstone M; Pannell R
Thromb Haemost; 1994 Mar; 71(3):347-52. PubMed ID: 8029800
[TBL] [Abstract][Full Text] [Related]
27. Involvement of alpha v beta 3 integrin in mediating fibrin gel retraction.
Katagiri Y; Hiroyama T; Akamatsu N; Suzuki H; Yamazaki H; Tanoue K
J Biol Chem; 1995 Jan; 270(4):1785-90. PubMed ID: 7530248
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the binding of human tissue-type plasminogen activator to platelets.
Vaughan DE; Mendelsohn ME; Declerck PJ; Van Houtte E; Collen D; Loscalzo J
J Biol Chem; 1989 Sep; 264(27):15869-74. PubMed ID: 2550424
[TBL] [Abstract][Full Text] [Related]
29. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
[TBL] [Abstract][Full Text] [Related]
30. Effects of ionic and nonionic contrast media on clot structure, platelet function and thrombolysis mediated by tissue plasminogen activator in plasma clots.
Carr ME; Carr SL; Merten SR
Haemostasis; 1995; 25(4):172-81. PubMed ID: 7557656
[TBL] [Abstract][Full Text] [Related]
31. The potential role of platelet PAl-1 in t-PA mediated clot lysis of platelet rich plasma.
Serizawa K; Urano T; Kozima Y; Takada Y; Takada A
Thromb Res; 1993 Aug; 71(4):289-300. PubMed ID: 8236158
[TBL] [Abstract][Full Text] [Related]
32. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
33. Endogenous fibrinolysis facilitates clot retraction in vivo.
Samson AL; Alwis I; Maclean JAA; Priyananda P; Hawkett B; Schoenwaelder SM; Jackson SP
Blood; 2017 Dec; 130(23):2453-2462. PubMed ID: 29074499
[TBL] [Abstract][Full Text] [Related]
34. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography.
Katori N; Tanaka KA; Szlam F; Levy JH
Anesth Analg; 2005 Jun; 100(6):1781-1785. PubMed ID: 15920213
[TBL] [Abstract][Full Text] [Related]
35. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
[TBL] [Abstract][Full Text] [Related]
36. PAI-1 inhibition enhances the lysis of the platelet-rich part of arterial-like thrombi formed in vitro. A comparative study using thrombi prepared from rat and human blood.
van Giezen JJ; Nerme V; Abrahamsson T
Blood Coagul Fibrinolysis; 1998 Jan; 9(1):11-8. PubMed ID: 9607114
[TBL] [Abstract][Full Text] [Related]
37. Imaging analyses of coagulation-dependent initiation of fibrinolysis on activated platelets and its modification by thrombin-activatable fibrinolysis inhibitor.
Brzoska T; Suzuki Y; Sano H; Suzuki S; Tomczyk M; Tanaka H; Urano T
Thromb Haemost; 2017 Apr; 117(4):682-690. PubMed ID: 28150854
[TBL] [Abstract][Full Text] [Related]
38. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin.
Podor TJ; Peterson CB; Lawrence DA; Stefansson S; Shaughnessy SG; Foulon DM; Butcher M; Weitz JI
J Biol Chem; 2000 Jun; 275(26):19788-94. PubMed ID: 10764803
[TBL] [Abstract][Full Text] [Related]
39. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
40. Platelets interact with fibrin only after activation.
Hantgan RR; Taylor RG; Lewis JC
Blood; 1985 Jun; 65(6):1299-311. PubMed ID: 3888311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
